Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Manufacturers Notice of Application - 2003 > Sigma Aldrich Research Biochemicals, Inc.

Manufacturers Notice of Application - 2003

FR Doc 03-29963 [Federal Register: December 2, 2003 (Volume 68, Number 231)] [Notices] [Page 67479-67480] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr02de03-106]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on September 18, 2003, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug Schedule 
Cathinone (1235) I
Methcathinone (1237) I
Aminorex (1585) I
Alpha-ethyltryptamine (7249) I
Lysergic acid diethylamide (7315) I
Tetrahydrocannabinols (7370) I
4-Bromo-2,5-dimethoxy-amphetamine (7391) I
4-Bromo-2,5-dimethoxyphenethylamine (7392) I
2,5-Dimethoxyamphetamine (7396) I
3,4-Methylenedioxyamphetamine (7400) I
N-Hydroxy-3,4-methylenedioxyamphetamine  (7402) I
3,4-Methylenedioxy-N-ethylamphetamine  (7404) I
3,4-Methylenedioxymethamphetamine (MDMA) (7405) I
1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) (7470) I
Heroin (9200) I
Normorphine (9313) I
Amphetamine (1100) II
Methamphetamine (1105) II
1-Phenylcyclohexylamine (7460) II
Phencyclidine (7471) II
Cocaine (9041) II
Codeine (9050) II
Diprenorphine (9058) II
Ecgonine (9180) II
Levomethorphan (9210) II
Levorphanol (9220) II
Meperidine (9230) II
Metazocine (9240) II
Methadone (9250) II
Morphine (9300) II
Thebaine (9333) II
Levo-alphacetylmethadol (9648) II
Carfentanil (9743) II
Fentanyl (9801) II

The firm plans to manufacture the listed controlled substances for laboratory reference standards and neurochemicals. 

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration. 

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than February 2, 2004.

November 14, 2003. 

Laura M. Nagel, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. 

[FR Doc. 03-29963 Filed 12-01-03; 8:45 am]

BILLING CODE 4410-09-M

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility